This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

EMPA - KIDNEY

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

EMPA-KIDNEY

  • was a RCT of 6609 patients with chronic kidney disease who were randomized to the SGLT2 inhibitor empagliflozin or placebo
  • effect of treatment on CVD, progression of kidney disease, and the need for hospitalization in patients with chronic kidney disease was investigated
  • mean follow-up was 2.0 years

  • treatment with empagliflozin reduced progression (i.e. worsening) of kidney disease or CV death by 28% compared to placebo
    • a consistent benefit was observed in those with or without CVD

  • EMPA-KIDNEY showed consistent benefits among 3569 patients (54.0%) without diabetes and, separately, among 2282 patients (34.5%) with an eGFR of less than 30 ml per minute per 1.73 m2

  • the need for hospitalization by any cause was reduced by 14% in the group who received empagliflozin compared to the group who received placebo

EMPA-KIDNEY trial in patients with chronic kidney disease showed that treatment with empagliflozin reduced the progression of kidney disease or CV death and reduced the need for all-cause hospitalization.

  • similar benefit for treatment with empagliflozin was seen regardless of CVD status

Reference:

  • The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. NEJM; November 4, 2022 DOI: 10.1056/NEJMoa2204233

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.